Terms: = Head and neck cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2
10 results:
1. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL] [Abstract] [Full Text] [Related]
2. Daurisoline suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting MEK1/2 kinase.
Wang D; Zhang W; Zhang X; Li M; Wu Q; Li X; Zhao L; Yuan Q; Yu Y; Lu J; Zhao J; Dong Z; Liu K; Jiang Y
Mol Carcinog; 2023 Apr; 62(4):517-531. PubMed ID: 36645220
[TBL] [Abstract] [Full Text] [Related]
3. Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
Xie X; Zu X; Liu F; Wang T; Wang X; Chen H; Liu K; Wang P; Liu F; Zheng Y; Bode AM; Dong Z; Kim DJ
Mol Carcinog; 2019 Jul; 58(7):1248-1259. PubMed ID: 31100197
[TBL] [Abstract] [Full Text] [Related]
4. Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA; Dinh CT; Vitte J; Kirkpatrick J; Mindos T; Plati SK; Young JI; Huang J; Carlstedt A; Franco MC; Brnjos K; Nagamoto J; Petrilli AM; Copik AJ; Soulakova JN; Bracho O; Yan D; Mittal R; Shen R; Telischi FF; Morrison H; Giovannini M; Liu XZ; Chang LS; Fernandez-Valle C
Neuro Oncol; 2019 Mar; 21(4):486-497. PubMed ID: 30615146
[TBL] [Abstract] [Full Text] [Related]
5. Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy.
Gomez-Millan J; Pajares B; Perez-Villa L; Carnero A; Alvarez M; De Luque V; Rivas F; Trigo JM; Toledo MD; Alba E; Medina JA
BMC Cancer; 2016 Oct; 16(1):829. PubMed ID: 27793200
[TBL] [Abstract] [Full Text] [Related]
6. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid cancer.
Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
[TBL] [Abstract] [Full Text] [Related]
7. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; DomÃnguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
[TBL] [Abstract] [Full Text] [Related]
8. The CDKN2A and MAP kinase pathways: molecular roads to primary oral mucosal melanoma.
Hsieh R; Nico MM; Coutinho-Camillo CM; Buim ME; Sangueza M; Lourenço SV
Am J Dermatopathol; 2013 Apr; 35(2):167-75. PubMed ID: 23000904
[TBL] [Abstract] [Full Text] [Related]
9. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of the fine needle aspiration biopsy in the preoperative selection of cold thyroid nodules.
La Rosa GL; Belfiore A; Giuffrida D; Sicurella C; Ippolito O; Russo G; Vigneri R
Cancer; 1991 Apr; 67(8):2137-41. PubMed ID: 2004334
[TBL] [Abstract] [Full Text] [Related]
